Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 41Non-Muscle Invasive Bladder Neoplasms 25Colorectal Neoplasms 20Anus Neoplasms 17Carcinoma, Transitional Cell 15Neoplasm Metastasis 12Carcinoma, Hepatocellular 10Appendiceal Neoplasms 10Stomach Neoplasms 9Peritoneal Neoplasms 9Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Lung Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 5Liver Neoplasms 5Sarcoma 4Anal Canal Carcinoma 4Urologic Neoplasms 3Urologic Diseases 3Urinary Bladder Diseases 3Pseudomyxoma Peritonei 3Mesothelioma, Malignant 3Gastrointestinal Neoplasms 3Carcinoma in Situ 3Carcinoma 3Breast Neoplasms 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2

Interventions

Cisplatin 55Carboplatin 49pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Docetaxel 17Cetuximab 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 12Radiation 11Sorafenib 10Platinum 10130-nm albumin-bound paclitaxel 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Sunitinib 8Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma × Mitomycin × Clear all
NCT02526953 2021-02-09

Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients

Blokhin's Russian Cancer Research Center

Phase 3 Unknown
314 enrolled
Gastrointestinal

Anus Diseases, Anus Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Neoplasms, Neoplasms, Squamous Cell

NCT02793128 2020-12-22

Olympus

UroGen Pharma Ltd.

Phase 3 Completed
71 enrolled 16 charts 1 FDA
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

NCT04006691 2020-05-07

Retreatment

UroGen Pharma Ltd.

Phase 3 Withdrawn
Genitourinary

Carcinoma, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡